UCB (OTCMKTS:UCBJY) Lowered to Strong Sell Rating by Zacks Research

UCB (OTCMKTS:UCBJY) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Thursday,Zacks.com reports.

Separately, Wolfe Research upgraded UCB to a “strong-buy” rating in a report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, UCB currently has a consensus rating of “Buy”.

UCB Price Performance

UCB stock opened at $158.72 on Thursday. UCB has a 52-week low of $89.00 and a 52-week high of $168.76. The stock’s 50 day moving average price is $145.77 and its two-hundred day moving average price is $147.17. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.